Importer of Record, US Agent, US Sponsor: Three Roles, Three Regulations Every Non-US Device Maker Must Understand

The Rule That Catches Non-US Device Companies Off Guard

Under 21 CFR 812.18(a), a company located outside the United States cannot itself sponsor an FDA Investigational Device Exemption (IDE) study. A US person must assume the sponsor role and carry every obligation enumerated in 21 CFR Part 812, from protocol submission through adverse event reporting and device accountability. This is not a procedural technicality. It is a hard legal boundary that shapes how non-US manufacturers must structure their US clinical and commercial strategy from day one.

Three Roles in One Pass

The Importer of Record satisfies US Customs and FDA entry obligations at the port. The US Agent under 21 CFR 807.40 serves as the FDA's designated point of contact for a foreign device establishment, handling correspondence and submissions. The US Sponsor under 21 CFR Part 812 assumes full legal accountability for an IDE study conducted on US soil, including every regulatory, safety, and reporting duty the foreign manufacturer cannot hold directly. These roles can overlap in one entity or be distributed across multiple parties, but each carries its own distinct legal weight.

Three Column Comparison: What Each Role Owns and Does Not Own

Importer of Record (19 USC 1484 and 21 CFR Part 1)

• Legally responsible for: Filing entry documentation with US Customs and Border Protection; paying applicable duties and fees; presenting devices for FDA examination at entry; ensuring devices are not detained or refused under 21 CFR Part 1; maintaining records of importation for FDA inspection.
• Not responsible for: Interacting with FDA on device registration or listing matters; managing IDE protocol obligations; submitting 510(k), PMA, or IDE applications; responding to FDA warning letters or establishment inspection observations; serving as a regulatory contact for ongoing device oversight.

US Agent (21 CFR 807.40)

• Legally responsible for: Serving as FDA's official point of contact for the foreign establishment; forwarding FDA communications to the foreign manufacturer within one business day; assisting FDA in scheduling inspections of the foreign site; being physically located in the United States and reachable during business hours.
• Not responsible for: Signing IDE applications or assuming sponsor obligations; making regulatory decisions on behalf of the manufacturer; submitting premarket notifications or approval applications unless separately contracted; bearing liability for device defects, adverse events, or clinical trial conduct.

US Sponsor (21 CFR Part 812)

• Legally responsible for: Submitting and holding the IDE application; selecting qualified investigators; monitoring study conduct and device accountability; submitting progress reports, adverse device effect reports, and IDE amendments to FDA; ensuring informed consent procedures comply with 21 CFR Part 50; maintaining all records required under 21 CFR 812.140.
• Not responsible for: Customs clearance or import entry filing (unless also acting as importer); routine establishment correspondence handled separately by the US Agent.

How an IDE Shipment Triggers the 812.18(a) Layer on Top of Ordinary Import Rules

When a non-US manufacturer ships investigational devices into the United States for a clinical study, the shipment crosses two distinct regulatory layers simultaneously. The first layer is ordinary import law: 19 USC 1484 requires an Importer of Record to file entry, and 21 CFR Part 1 authorizes FDA to examine and potentially detain devices at the border. Many companies handle this layer without incident.

The second layer activates the moment those devices are investigational. 21 CFR 812.18(a) states: 'A sponsor that is not a citizen or resident of the United States shall designate a citizen or resident of the United States as the sponsor's representative and as the sponsor of the IDE, who accepts responsibility for compliance with applicable regulations.' (21 CFR 812.18(a)). This means the Importer of Record satisfying Customs has done nothing to satisfy the IDE sponsor requirement. A separate, legally accountable US Sponsor must exist before FDA will process the IDE, before investigators can enroll a single subject, and before devices can be lawfully distributed for investigational use.

Conflating these two layers is one of the most common and costly compliance errors ADB reviews in non-US device programs. The import clears; the study stalls because no qualified US Sponsor is in place.

Lower Cost Entry Point: US Agent Designation

If your device is already cleared or approved and you need only a US regulatory contact to satisfy 21 CFR 807.40, you do not need a full US Sponsor engagement. ADB offers a structured US Agent designation service at adbccro.com/us-agent that covers FDA correspondence forwarding, inspection coordination, and establishment communication without the broader accountability framework that an IDE program requires. This is the appropriate starting point for foreign establishments in commercial distribution who are not yet conducting US clinical investigations.

When You Need Full US Sponsor of Record Coverage

For companies preparing an IDE submission or assessing a US pivotal study strategy, the sponsor obligation is non-delegable and nontrivial. ADB Consulting and CRO Inc. serves as US Sponsor of Record for non-US medical device manufacturers conducting FDA-regulated clinical investigations in the United States, assuming all regulatory obligations under 21 CFR Part 812 so that the foreign manufacturer can focus on device development and global commercialization. Learn more at adbccro.com/us-sponsor.

Frequently Asked Questions

Can our European notified body approval substitute for a US Sponsor designation under 21 CFR Part 812?

No. CE marking and notified body certification operate under EU MDR and have no legal standing within the FDA regulatory framework. An IDE study requires a US Sponsor regardless of what approvals exist in other jurisdictions. FDA assesses only compliance with 21 CFR Part 812 when reviewing an IDE application.

If we contract with a US CRO to run our clinical trial, does the CRO automatically become our US Sponsor?

Not automatically. Sponsor obligations under 21 CFR Part 812 must be explicitly assigned through a written agreement, and the CRO must affirmatively accept those responsibilities. Many CROs manage operations without accepting sponsor status. You should review any CRO agreement carefully and prepare a clear sponsor delegation document before IDE submission to avoid regulatory gaps.

What is the difference between a nonsignificant risk device study and a significant risk study in terms of the 812.18(a) US Sponsor requirement?

Both require a US Sponsor if the manufacturer is non-US. The nonsignificant risk pathway allows an abbreviated IDE under 21 CFR 812.2(b) without a formal FDA submission, but the sponsor obligations related to IRB oversight, informed consent, device accountability, and adverse event reporting still apply. The US Sponsor must be in place either way before the study begins.

Reviewed October 19, 2026 by ADB's regulatory team.

Book a Free Discovery Call

If your organization is assessing a US IDE study, preparing a non-US establishment registration, or reviewing your current sponsor and agent structure, ADB Consulting and CRO Inc. is ready to help. Book a free discovery call with Andre Butler and the ADB regulatory team today.

Related reading: our US Sponsor of Record service covers this in more depth.